Press releases

AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director

AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director

AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director

AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director

AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director

AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director

30 March 2020

NORTH CHICAGO, Ill., March 30, 2020 /PRNewswire/ -- AbbVie issued the following form today.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION
Name of person dealing (Note 1)	Richard Gonzalez
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	25 March 2020

2. INTERESTS AND SHORT POSITIONS (a)Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	377,893 Common Shares (0.00025%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	1,161,286 options (0.0008%)
Total	1,539,178 (0.00104%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4) (a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Withholding of common shares to satisfy tax obligations	56,950 common shares	$0

(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities (i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising
Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)	YES/NO√
Date of disclosure	27 March 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---statement-of-stock-purchase-by-director-301031478.html

SOURCE AbbVie

4 March 2020

NORTH CHICAGO, Ill., March 4, 2020 /PRNewswire/ -- AbbVie issued the following form today.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION
Name of person dealing (Note 1)	Edward J. Rapp
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	3 March 2020



2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	33,537 Common Shares (0.00002%)
(2) Derivatives (other than options)	16,872 Stock Equivalent Units
(3) Options and agreements to purchase/sell	N/A
Total	50,409 (0.00003%)



(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total



3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Purchase by spouse in trust	2,875 common shares	$87.87



(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)



(ii) Exercising
Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)



(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.



Is a Supplemental Form 8 attached? (Note 9)	YES/NO√
Date of disclosure	3 March 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---statement-of-stock-purchase-by-director-301016914.html

SOURCE AbbVie

3 March 2020

NORTH CHICAGO, Ill., March 3, 2020 /PRNewswire/ -- AbbVie issued the following forms today.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION
Name of person dealing (Note 1)	AbbVie Inc.
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	2 March 2020

2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	N/A
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	N/A

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Share buyback	1,149,900	$86.9413

(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising
Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Is a Supplemental Form 8 attached? (Note 9)	YES/NO√
Date of disclosure	3 March 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	AbbVie Inc.

1. KEY INFORMATION
Name of person dealing (Note 1)	AbbVie Inc.
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	3 March 2020

2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	N/A
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	N/A

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Share buyback	1,139,300	$87.7667

(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising
Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Is a Supplemental Form 8 attached? (Note 9)	YES/NO√
Date of disclosure	4 March 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	AbbVie Inc.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---statement-of-stock-purchase-by-director-301015976.html

SOURCE AbbVie

2 March 2020

NORTH CHICAGO, Ill., March 2, 2020 /PRNewswire/ -- AbbVie issued the following forms today.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION
Name of person dealing (Note 1)	AbbVie Inc.
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	28 February 2020

2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	N/A
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	N/A
Total	N/A

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Share buyback	2,452,782	$83.654

(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising
Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Is a Supplemental Form 8 attached? (Note 9)	YES/NO√
Date of disclosure	2 March 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	AbbVie Inc.

1. KEY INFORMATION
Name of person dealing (Note 1)	Richard Gonzalez
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	21 February 2020

2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	523,561 Common Shares (0.0004%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	1,161,286 options (0.0008%)
Total	1,684,847 (0.0011%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Issue of common shares pursuant to AbbVie equity award plans	200,262 common shares	$0
Gift of common shares	3,675 common shares	$0

(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising
Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Is a Supplemental Form 8 attached? (Note 9)	YES/NO√
Date of disclosure	2 March 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

1. KEY INFORMATION
Name of person dealing (Note 1)	Richard Gonzalez
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	28 February 2020

2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	434,843 Common Shares (0.0004%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	1,161,286 options (0.0008%)
Total	1,596,128 (0.0011%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Withholding of common shares to satisfy tax obligations	88,719 common shares	$0

(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising
Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)
Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Is a Supplemental Form 8 attached? (Note 9)	YES/NO√
Date of disclosure	2 March 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---statement-of-stock-purchase-by-director-301014871.html

SOURCE AbbVie

9 January 2020

NORTH CHICAGO, Ill., Jan. 9, 2020 /PRNewswire/ -- AbbVie issued the following forms today.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION
Name of person dealing (Note 1)	Edward Rapp
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	31 December 2019

2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	30,662 (0.002%)
(2) Derivatives (other than options)	16,872 (0.001%)
(3) Options and agreements to purchase/sell	N/A
Total	47,534 (0.003%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)

(b) Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

Stock equivalent unit

Director fee credit to stock equivalent unit account

384

$88.54

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising

Product name,

e.g. call option

Number of securities

Exercise price

per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Is a Supplemental Form 8 attached? (Note 9)	YES/NO√
Date of disclosure	8 January 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

1. KEY INFORMATION
Name of person dealing (Note 1)	Edward Liddy
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	31 December 2019

2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	22,669 (0.002%)
(2) Derivatives (other than options)	24,692 (0.002%)
(3) Options and agreements to purchase/sell	N/A
Total	47,361 (0.003%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)

(b) Derivatives transactions (other than options transactions)
Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)
Stock equivalent unit	Director fee credit to stock equivalent unit account	367	$88.54

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising

Product name,

e.g. call option

Number of securities

Exercise price per

unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Is a Supplemental Form 8 attached? (Note 9)	YES/NO√
Date of disclosure	8 January 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

1. KEY INFORMATION
Name of person dealing (Note 1)	Robert Alpern
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	31 December 2020

2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)
	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	26,107 (0.002%)
(2) Derivatives (other than options)	6,933 (0.000%)
(3) Options and agreements to purchase/sell	N/A
Total	33,040 (0.002%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A
Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/sale	Number of relevant securities	Price per unit (Note 5)

(b) Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

Stock equivalent unit

Director fee credit to stock equivalent unit account

$88.54

(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising

Product name,

e.g. call option

Number of securities

Exercise price per

unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Is a Supplemental Form 8 attached? (Note 9)	YES/NO√
Date of disclosure	8 January 2020
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---statement-of-stock-purchase-by-director-300984678.html

SOURCE AbbVie

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

16 December 2019

NORTH CHICAGO, Ill., Dec. 16, 2019 /PRNewswire/ -- AbbVie issued the following forms today.

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

Name of person dealing (Note 1)	Richard Gonzalez
Company dealt in	AbbVie Inc.
Class of relevant security to which the dealings being disclosed relate (Note 2)	Common shares, par value $0.01 per share
Date of dealing	4 December 2019

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities	334,589 Common Shares (0.02%)
(2) Derivatives (other than options)	N/A
(3) Options and agreements to purchase/sell	932,154 options (0.06%)
Total	1,266,743 (0.09%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

3. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit (Note 5)
Gift of common shares	4,000 common shares	$0

(b) Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit (Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii) Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Is a Supplemental Form 8 attached? (Note 9) YES/NO√

Date of disclosure	16 December 2019
Contact name	Steven L. Scrogham
Telephone number	847-938-6166
Name of offeree/offeror with which acting in concert	AbbVie Inc.
Specify category and nature of acting in concert status	Director of AbbVie Inc.

View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---statement-of-stock-purchase-by-director-300975487.html

SOURCE AbbVie